Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.
- DOI
- 10.1016/j.cardfail.2026.02.045
- Published
- 2026-05-01
- Container
- J Card Fail
- Publisher
- Not recorded
- Open access
- no
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.cardfail.2026.02.045,
title = {Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.},
author = {Ambardekar AV and Sarswat N and Wright R and Berk J and Davis MK and Garcia-Pavia P and Gillmore JD and Grodin JL and Mitchell JD and Mooney D and Nativi-Nicolau J and Poulsen SH and Ruberg FL and Chen C and Ji A and Siddhanti S and Tamby JF and Castaño A and Katz L and Sinha U and Fox JC and Maurer MS and Cheng RK.},
year = {2026},
journal = {J Card Fail},
doi = {10.1016/j.cardfail.2026.02.045},
url = {https://doi.org/10.1016/j.cardfail.2026.02.045}
}RIS
TY - JOUR TI - Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial. AU - Ambardekar AV AU - Sarswat N AU - Wright R AU - Berk J AU - Davis MK AU - Garcia-Pavia P AU - Gillmore JD AU - Grodin JL AU - Mitchell JD AU - Mooney D AU - Nativi-Nicolau J AU - Poulsen SH AU - Ruberg FL AU - Chen C AU - Ji A AU - Siddhanti S AU - Tamby JF AU - Castaño A AU - Katz L AU - Sinha U AU - Fox JC AU - Maurer MS AU - Cheng RK. PY - 2026 JO - J Card Fail DO - 10.1016/j.cardfail.2026.02.045 UR - https://doi.org/10.1016/j.cardfail.2026.02.045 ER -
APA
AV, A., N, S., R, W., J, B., MK, D., P, G., JD, G., JL, G., JD, M., D, M., J, N., SH, P., FL, R., C, C., A, J., S, S., JF, T., A, C., L, K., U, S., JC, F., MS, M., & RK., C. (2026). Acoramidis, Serum Transthyretin, and Cardiovascular Outcomes in Transthyretin Amyloid Cardiomyopathy: Insights From the ATTRibute-CM Trial.. J Card Fail. https://doi.org/10.1016/j.cardfail.2026.02.045
Source records
- europe-pmc · retrieved 2026-09-25T21:15:36.008Z